Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Interest & Investment Income (2016 - 2026)

Corvus Pharmaceuticals' Interest & Investment Income history spans 7 years, with the latest figure at $1.8 million for Q1 2026.

  • Quarterly Interest & Investment Income rose 239.81% to $1.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Mar 2026, up 85.15% year-over-year, with the annual reading at $2.5 million for FY2025, 37.34% up from the prior year.
  • Interest & Investment Income came in at $1.8 million for Q1 2026, up from $603000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.8 million in Q1 2026 to a low of $316000.0 in Q1 2024.
  • The 3-year median for Interest & Investment Income is $566000.0 (2024), against an average of $679222.2.
  • Year-over-year, Interest & Investment Income increased 18.7% in 2025 and then soared 239.81% in 2026.
  • Corvus Pharmaceuticals' Interest & Investment Income stood at $508000.0 in 2024, then increased by 18.7% to $603000.0 in 2025, then soared by 195.85% to $1.8 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Interest & Investment Income are $1.8 million (Q1 2026), $603000.0 (Q4 2025), and $738000.0 (Q3 2025).